Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 167 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/22/2008 First Published: 7/1/1999


1.		Phase II/III Study of Standard and Novel Conditioning Therapy and Allogeneic Blood or Marrow Transplantation in Patients With Severe Aplastic Anemia or Hematologic Malignancy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				4 to 70				Other				RPCI-RP-9815 NCI-V99-1527, NCT00003816, RP 98-15

Last Modified: 6/9/2008 First Published: 9/26/2007


2.		Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				4 and over				NCI				RPCI-I-72806 I 72806, NCT00536601


3.		Non-Myeloablative Allogeneic HSCT From HLA Matched Related Donors for the Treatment of Low Grade B Cell Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				19 to 70				Other				F080429003 UAB-0775, NCT00714259

Last Modified: 8/6/2008 First Published: 2/16/2007


4.		Phase III Randomized Study of Filgrastim (G-CSF)-Mobilized Matched-Sibling Donor Peripheral Blood Stem Cell Transplantation Versus G-CSF-Stimulated Matched-Sibling Donor Bone Marrow Transplantation in Patients With Hematologic Malignancies or Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				16 to 65				NCI				CBMTG-0601 NCT00438958

Last Modified: 8/8/2007 First Published: 3/1/2001


5.		Phase I/II Study of Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab With and Without Filgrastim (G-CSF) and Interleukin-11 in Patients With Relapsed or Refractory Low-Grade or Follicular CD20+ Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				MAYO-MC998C NCI-312, NCT00012298

Last Modified: 2/16/2007 First Published: 5/23/2005


6.		Phase I/II Pilot Study of Flavopiridol in Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				OSU-04100 OSU-2005C0006, NCI-7002, 7002, NCT00112723


7.		Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI, Other				LYMNHL0014 80057, LYMNHL0014, NCT00185965, NIH, NCT00185965

Last Modified: 4/30/2007 First Published: 2/17/2006


8.		Phase I/II Study of Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Patients With Relapsed or Refractory Indolent B-Cell Lymphoproliferative Disorders or Mantle Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				MSKCC-05103 NCT00295932

Last Modified: 9/29/2008 First Published: 1/25/2006


9.		Phase I/II Study of Fenretinide and Rituximab in Patients With B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				WU-6071 6071, FHCRC-6071, NCI-6957, 6957, UWCC-UW-6071, UWCC-06-0644-H/A, NCT00288067


10.		A Study of SB-743921 in Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				CY 2121 NCT00343564

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute